#Peptide Receptor Radionuclide Therapy (PRRT) Market Outlook | Explore Tumblr posts and blogs

exp-market-research111 · 3 days ago

Text

Carcinoid Tumor Drug Pipeline Analysis Report 2024

Carcinoid Tumor Market Outlook

Carcinoid tumors are uncommon, representing roughly 0.5% of all cancers. Typically diagnosed in individuals around their early 60s, these tumors mainly occur in the gastrointestinal system. In the United States, approximately 8,000 new cases of carcinoid tumors are reported annually. Treatment options include surgical intervention, chemotherapy, targeted therapies, and the development of new immunotherapies. These innovative treatments focus on slowing tumour growth and enhancing patient prognosis.

Carcinoid Tumor: Introduction

Carcinoid tumours are rare, slow-growing neuroendocrine tumours that typically develop in the gastrointestinal tract, lungs, or other endocrine organs. These tumours secrete hormones, such as serotonin, which can lead to a condition called carcinoid syndrome, characterised by symptoms like diarrhoea, flushing, and wheezing. Diagnosis often occurs late due to the insidious nature of symptoms, making treatment challenging. The development of new therapies focuses on controlling tumour growth, managing hormone secretion, and improving patient quality of life. Ongoing clinical trials and drug innovations are crucial to addressing the unmet needs in the treatment of these rare tumours.

Get a Free Sample Report with Table of Contents: https://www.expertmarketresearch.com/clinical-trials/carcinoid-tumor-drug-pipeline-analysis/requestsample

Carcinoid Tumor Treatment Overview

Carcinoid tumours are typically treated with surgical resection if possible, alongside therapies that control tumour growth and hormone secretion. The main treatment approaches include somatostatin analogues to reduce symptoms, chemotherapy for advanced disease, and targeted therapies. Early-stage disease may be managed with surgery alone, while more advanced stages require a combination of therapies, including systemic treatments and novel therapies under investigation.

Treatment options include somatostatin analogues such as octreotide and lanreotide to manage symptoms. Other approaches include chemotherapy, targeted therapies, and peptide receptor radionuclide therapy (PRRT). Targeted drugs, such as mTOR inhibitors and tyrosine kinase inhibitors, are emerging as promising options in advanced or resistant cases.

Drug Pipeline Therapeutic Assessment

Analysis by Route of Administration

Oral

Parenteral

Others

Analysis by Phase

Preclinical Phase

Phase I

Phase II

Phase III

Phase IV

Analysis by Drug Class

Monoclonal Antibody

Peptides

Polymer

Small Molecule

Gene Therapy

Carcinoid Tumor Drug Classes

Carcinoid tumor treatments utilise a range of drug classes, each designed to target specific pathways and mechanisms involved in cancer growth and survival. These diverse classes enhance the effectiveness of therapy and contribute to personalised treatment strategies. Understanding these drug classes is essential for optimising patient outcomes.

Monoclonal Antibody

Monoclonal antibodies are laboratory-engineered molecules designed to target specific antigens on the surface of tumour cells, which helps to block their growth and enhances the immune system's ability to destroy them. In carcinoid tumours, these antibodies may target receptors that drive hormone secretion or tumour proliferation, improving disease control. By blocking key growth signals or immune evasion mechanisms, monoclonal antibodies offer an effective and precise treatment strategy for managing advanced or metastatic carcinoid tumours.

Peptides

Peptide-based therapies consist of short chains of amino acids that can interfere with the processes responsible for tumour growth. In carcinoid tumours, somatostatin analogues are commonly used, which bind to specific receptors on the tumour cells, inhibiting the release of excess hormones such as serotonin. These therapies help to manage symptoms like flushing and diarrhoea associated with carcinoid syndrome, and stabilise tumour growth, offering symptom relief and improving patients’ quality of life.

Polymer

Polymers play an important role in cancer therapy by improving the delivery and stability of drugs. In carcinoid tumours, polymer-based drug delivery systems are used to target therapies more efficiently to the tumour site. This enhances the effectiveness of drugs by increasing their concentration at the tumor while reducing side effects on healthy tissues. Such advanced delivery mechanisms help to improve therapeutic outcomes, particularly for patients with advanced, resistant, or metastatic disease.

Small Molecule

Small molecules are drugs that are small enough to enter cells and interfere with cellular pathways responsible for tumour growth and survival. In carcinoid tumours, small molecules target specific signalling pathways involved in tumour proliferation and hormone production. By modulating these pathways, small molecules can help slow down tumour growth, manage symptoms, and provide an effective option for treating progressive or metastatic carcinoid tumours, where traditional therapies may be less effective.

Gene Therapy

Gene therapy aims to address the underlying genetic causes of cancer by modifying or replacing defective genes in tumour cells. For carcinoid tumours, gene therapy is being investigated to either restore normal cellular function or enhance the immune system’s ability to recognise and destroy tumour cells. This approach holds promise for offering long-term solutions in treating hard-to-treat, resistant cases of carcinoid tumours by targeting the molecular drivers of tumour growth.

Carcinoid Tumor- Pipeline Drug Profiles

This section provides an overview of the various drugs used to treat carcinoid tumor. It covers their classifications, mechanisms of action, and methods of administration, offering essential insights for effective treatment strategies.

40 mg Paltusotine

Paltusotine is a selective somatostatin receptor type 2 agonist that is being investigated for its potential to control hormone secretion in patients with carcinoid syndrome. By reducing the serum levels of serotonin, it helps to manage the symptoms of diarrhoea, flushing, and wheezing associated with the syndrome. Clinical trials have shown promising results, especially for patients who have not responded to other standard therapies, making it a potential new option for long-term management.

Pasireotide (SOM230)

Pasireotide is a multireceptor-targeted somatostatin analogue used to manage the symptoms associated with neuroendocrine tumours, including carcinoid syndrome. It works by binding to somatostatin receptors and inhibiting the release of hormones like serotonin, which causes symptoms like diarrhoea and flushing. Pasireotide has shown efficacy in clinical trials, particularly in patients whose symptoms are not adequately controlled by first-line treatments. It offers an alternative therapeutic option for patients with advanced or resistant cases.

Quarfloxin

Quarfloxin is an investigational small molecule that targets the mitochondrial DNA replication machinery in cancer cells, causing tumour cell death. In carcinoid tumours, quarfloxin is being evaluated for its potential to inhibit tumour growth, particularly in patients with advanced or metastatic disease. Early clinical trials are assessing the drug’s safety and efficacy, and its combination with other therapies is being explored to improve overall treatment outcomes and manage resistant cases of carcinoid tumour.

Carcinoid Tumor: Competitor Landscape

The key features of the report include patent analysis, clinical trials, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

Novartis Pharmaceuticals

Headquartered in Basel, Switzerland, Novartis is a global leader in pharmaceutical innovation, with a strong presence in the oncology space. The company is known for its contributions to neuroendocrine tumour treatments, including the development of Pasireotide (SOM230) for managing carcinoid syndrome. Novartis continues to advance its research into targeted therapies and combination treatments, aiming to improve survival and quality of life for patients with rare, difficult-to-treat cancers such as carcinoid tumours.

CASI Pharmaceuticals, Inc.

CASI Pharmaceuticals, located in Rockville, Maryland, USA, is a biotechnology company focused on the development of novel therapies for rare and difficult-to-treat cancers, including carcinoid tumours. The company’s pipeline includes therapies designed to target tumour growth and hormone secretion in neuroendocrine cancers. By developing precision medicine approaches, CASI aims to provide more effective treatment options for patients with advanced or refractory cases of carcinoid tumours, addressing an unmet need in this area of oncology.

Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals, headquartered in San Diego, California, USA, is a leading biotechnology firm focused on the development of innovative treatments for endocrine diseases, including carcinoid tumours. The company is advancing several drug candidates that aim to modulate hormonal pathways and inhibit tumour growth. Crinetics’ approach to precision medicine aims to provide more personalised and effective treatments for patients with neuroendocrine cancers, and their research is expected to significantly improve treatment outcomes for carcinoid tumour patients.

Other key players in the landscape include Molecular Insight Pharmaceuticals, Inc., Neotropix, Ipsen, Cylene Pharmaceuticals, Lexicon Pharmaceuticals, TerSera Therapeutics LLC, Trio Medicines Ltd., and Endo Pharmaceuticals.

We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report..

#healthcare #market research report #Carcinoid Tumor Drug Pipeline Analysis

0 notes

hauntedsheepwhispers · 3 years ago

Text

The Global Peptide Receptor Radionuclide Therapy (PRRT) Market size is anticipated to grow at a CAGR of 12.4% during the forecast period.

The Global Peptide Receptor Radionuclide Therapy (PRRT) Market size is anticipated to grow at a CAGR of 12.4% during the forecast period. Peptide receptor radionuclide therapy (PRRT) is functions as a therapy that can be performed by using somatostatin analog that is coupled with a radionuclide emitting beta radiation. The PART contains proteins similar to somatostatin which can be combined with a radionuclide that forms a special type of radiopharmaceutical called a radiopeptide. This radiopeptide is injected into the human or patient body and affects the tumor cells delivering a targeted high dose of radiation directly to the cancer cells. Peptide receptor radionuclide therapy (PRRT) provides disease management, closing care gaps, cost savings for providers, and better health outcomes. Furthermore, the platform also assists payers and providers to manage risk associated with reimbursement policies.

Get More Informative Report: https://www.quincemarketinsights.com/industry-analysis/peptide-receptor-radionuclide-therapy-prrt-market

Company profiled in this report based on Business overview, Financial data, Product landscape, Strategic outlook & SWOT analysis: Novartis, Australasian Gastro-Intestinal Trials Group, ITM Solucin, Allscripts Healthcare Solutions, Inc., Sarepta Therapeutics, Caribou, Finvector, Sangamo Therapists Inc., Sirion Biotech, bluebird bio.

Key Factors Impacting the Growth of Peptide Receptor Radionuclide Therapy (PRRT) Market:

· Technological advancements

· Increasing market demand for population health

· Increasing prevalence of the neuroendocrine tumors

· An increasing number of the patient pool

According to the report, the Peptide Receptor Radionuclide Therapy (PRRT) market report points out national and global business prospects and competitive conditions for Peptide Receptor Radionuclide Therapy (PRRT). Market size estimation and forecasts were given based on a detailed research methodology tailored to the conditions of the demand for Peptide Receptor Radionuclide Therapy (PRRT). The Peptide Receptor Radionuclide Therapy (PRRT) market has been segmented as By Disease Indication (Pancreatic - Neuroendocrine Tumor, Gastrointestinal Tract - Neuroendocrine Tumor, and Others), End User (Hospitals, Ambulatory Surgical Centers, Cancer Care Centers) . Historical background for the demand of Peptide Receptor Radionuclide Therapy (PRRT) has been studied according to organic and inorganic innovations in order to provide accurate estimates of the market size. Primary factors influencing the growth of the demand Peptide Receptor Radionuclide Therapy (PRRT) have also been established with potential gravity.

Regional segmentation and analysis to understand growth patterns: The market has been segmented in major regions to understand the global development and demand patterns of this market. By region, the Peptide Receptor Radionuclide Therapy (PRRT) market has been segmented in North America, Europe, Asia Pacific, Middle East & Africa, and South America. The North America and Western Europe regions are estimated to register a stable demand during the forecast period with market recovery from recent slowdowns.

This report provides: 1) An overview of the global market for Peptide Receptor Radionuclide Therapy (PRRT) market and related technologies. 2) Analysis of global market trends, yearly estimates, and annual growth rate projections for compounds (CAGRs). 3) Identification of new market opportunities and targeted consumer marketing strategies for the global Peptide Receptor Radionuclide Therapy (PRRT) market. 4) Analysis of R&D and demand for new technologies and new applications 5) Extensive company profiles of key players in the industry.

The researchers have studied the market in-depth and have developed important segments such as product type, application, and region. Each and every segment and its sub-segments are analyzed based on their market share, growth prospects, and CAGR. Each market segment offers in-depth, both qualitative and quantitative information on market outlook.

Objectives of this report: • To estimate the market size for the Peptide Receptor Radionuclide Therapy (PRRT) market on a regional and global basis. • To identify major segments in the Peptide Receptor Radionuclide Therapy (PRRT) market and evaluate their market shares and demand. • To provide a competitive scenario for the Peptide Receptor Radionuclide Therapy (PRRT) market with major developments observed by key companies in the historic years. • To evaluate key factors governing the dynamics of the Peptide Receptor Radionuclide Therapy (PRRT) market with their potential gravity during the forecast period.

ABOUT US:

QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the world’s most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Contact:

Quince Market Insights

Office No- A109

Pune, Maharashtra 411028

Phone: APAC +91 706 672 4848 / US +1 208 405 2835 / UK +44 1444 39 0986

Email: [email protected]

Web: https://www.quincemarketinsights.com

0 notes

expertofmarketinsights-blog · 5 years ago

Text

Peptide Receptor Radionuclide Therapy (PRRT) Market Best Productivity Supply Chain Relationship, Development by 2026

Peptide receptor radionuclide therapy (PRRT) is a type of molecular therapy, also known as radioisotope therapy that is used for treating neuroendocrine tumors. In this therapy a peptide similar to the natural hormone is combined with radioactive material such as Yttrium and Lutetium, to produce radionuclide which is then injected into the patient’s body. This combination binds to the neuroendocrine tumors in the body. It is a cell targeting type of therapy since it delivers a high dose of radiation directly to the tumor cells. Click To Read More On Peptide Receptor Radionuclide Therapy (PRRT) Market.

Global Peptide Receptor Radionuclide Therapy (PRRT) Market Drivers

Increasing number of drug approvals by regulatory bodies is expected to drive the global peptide receptor radionuclide therapy market growth over the forecast period. For instance, in January 2018, Advanced Accelerator Applications S.A. received an approval from U.S. Food & Drug Administration for Lutathera, a peptide receptor radionuclide therapy. It is used for treating gastroenteropancreatic neuroendocrine tumors. Its phase 3 study showed 79% reduction in the disease progression. Moreover, it is the only approved peptide receptor radionuclide therapy drug.

Furthermore, key players are also focused on research and development activities related to peptide receptor radionuclide therapy which is expected to accelerate the global peptide receptor radionuclide therapy market growth. For instance, in July 2017, National Institute of Health commenced its clinical trial study on Y-DOTATOC. The drug is currently in the early phase of trials, and is being evaluated for micro-dosing. It will be used for treating neuroendocrine tumors. Such development of drugs is expected to boost the global peptide receptor radionuclide therapy market growth.

Also, strategies such as mergers, acquisitions, partnerships, and collaborations by key players related to peptide receptor radionuclide therapy are expected to propel the global peptide receptor radionuclide therapy market growth over the forecast period. For instance, in January 2018, Novartis AG, a biopharmaceutical company acquired Advanced Accelerator Applications S.A., a manufacturer of nuclear medicine products, in order to expand Novartis AG’s product portfolio. This acquisition was for the diversification of oncology neuroendocrine tumor treatment and addition of the radiopharmaceutical technology platform to its portfolio. The growing number of acquisitions are expected to fuel demand for the global peptide receptor radionuclide therapy market.

Global Peptide Receptor Radionuclide Therapy (PRRT) Market Taxonomy

The global peptide receptor radionuclide therapy (PRRT) market is segmented on the basis of disease indications, distribution channels, and regions.

By Disease Indication

Gastroenteropancreatic Neuroendocrine Tumor

Foregut Neuroendocrine Tumor

Midgut Neuroendocrine Tumor

Hindgut Neuroendocrine Tumor

By Distribution Channel

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Global Peptide Receptor Radionuclide Therapy (PRRT) Market Key Players

Some of the major player operating in the global peptide receptor radionuclide therapy (PRRT) market include, Novartis AG, ITM Solucin GmbH, National Institutes of Health, Australasian Gastro-Intestinal Trials Group, Toulouse University Hospital, Peking University, and others.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/2731

Global Peptide Receptor Radionuclide Therapy (PRRT) Market Regional Analysis

North America is expected to be a dominant region in the peptide receptor radionuclide therapy market. Higher incidences of prostate cancer is expected to support the global peptide receptor radionuclide therapy market growth. According to Center of Disease Control and Prevention’s data for 2016, around 192,443 people suffered from prostate cancer and almost 30,370 died due to it. Prostate cancer is considered the fourth leading cause of death due to cancer. Hence, increasing prevalence of prostate cancer is expected to augment the peptide receptor radionuclide therapy market growth during the forecast period.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Mr. Shah Coherent Market Insights 1001 4th Ave, #3200 Seattle, WA 98154 Tel: +1-206-701-6702 Email: [email protected]

#Peptide Receptor Radionuclide Therapy (PRRT) Market #Peptide Receptor Radionuclide Therapy (PRRT) Market sIze #Peptide Receptor Radionuclide Therapy (PRRT) Market Share #Peptide Receptor Radionuclide Therapy (PRRT) Market Outlook #Peptide Receptor Radionuclide Therapy (PRRT)

0 notes